ArticleGynecologic oncology2021

Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.

Gottfried E Konecny et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.